Hands-on course on Zebrafish Xenografts 2023 - 2nd edition

This course is promoted by Champalimaud Foundation's Fior Lab, integrated in the congento - Consortium for Genetically Tractable Organisms - initiatives.

The scientific programme will cover

- Protocols for preparation of human cancer cells for injection;
- Generation of zebrafish xenografts (microinjection in the perivitelline space);
- Metastatic assay;
- Protocols for immunofluorescence;
- Mounting xenografts for confocal imaging;
- Confocal session.

Venue

Champalimaud Center for the Unknown, Lisbon

23 November 2022

Expert commission report pinpoints unprecedented challenges faced by cancer research in Europe

A report, published last week (16 November) in The Lancet Oncology by an expert commission, under the title Key messages from European Groundshot – addressing Europe’s cancer research challenges: a Lancet Oncology Commission, analyses the current state of cancer research in Europe, identifies geographical and gender gaps (among others), and issues recommendations to rethink the priorities of European cancer research.

Fátima Cardoso, director of the Breast Unit at the Champalimaud Clinical Center/Champalimaud Foundation, is among the co-authors of the new report.

17 November 2022

Check Up #9 - Markers of cancer

Cancers can be detected through the presence, in the tumours or bodily fluids, of so-called molecular biomarkers – in other words, of biological molecules (proteins, genes, etc.) found in blood or tissues that are a sign that a person has cancer. One well-known cancer biomarker is the PSA protein, whose rapid rise in the blood may indicate the presence of prostate cancer. 

10 November 2022

Portuguese consortium to receive 78 million euros funding from the Programa de Recuperação e Resiliência to develop “responsible” AI

For every argument that construes AI as essential, promising and transforming across nearly all industries, there are voiced concerns about this technology. Many people do not trust AI, claiming that intelligent machines will one day dominate humankind. But while this is a remote possibility, the harm that can be done to people (albeit mostly unintentionally) by deep learning algorithms is very tangible – and has already been known to occur in the real world.

Daniela Cunha

04 November 2022

Work from Champalimaud Foundation Researcher Acknowledged by the Eppendorf & Science Prize for Neurobiology

After receiving her bachelor's degree in Biochemistry and a master's degree in Health Sciences from the University of Minho, which introduced her to the field of immunology, Cardoso embarked upon a PhD in the laboratory of Henrique Veiga-Fernandes at the Champalimaud Foundation to study the role of neuro-immune interactions in metabolism.

03 November 2022

Searching for the fine details of the complex interplay between cancer, metastases and their environment

Everything around a malignant tumour and its metastases, from its so-called microenvironment to the patients themselves as individuals, influences cancerous growth, and ultimately the outcome of the disease. This is the take-away message from CRSy2022 – the three-day international scientific symposium that took place at the Champalimaud Foundation, in Lisbon, from 19 to 21 October.

31 October 2022

Check Up #8 - Familial and hereditary cancer

All cancers are genetic in nature, in the sense that they all arise from genetic mutations inside cells. But the origin of those mutations can vary: they can be due to environmental factors (for example exposure to carcinogenic substances such as tobacco smoke or asbestos particles), but also to spurious DNA replication errors during the cellular division of any cell type in the body. Such random, unpredictable DNA errors account for nearly two-thirds of the mutations responsible for cancer.

31 October 2022

The importance of being translational

Helena Gouveia, oncologist at the Breast Unit of the Champalimaud Foundation (CF) tells us about two important examples of collaborative endeavours between this Unit and CF’s research labs. Scientists and clinicians join efforts to do translational research/medicine – that is, to take recent scientific advances “to the patients’ bedside” as safely, quickly and efficiently as possible.

31 October 2022

Immunotherapy against the most aggressive breast cancers

In this short video, Marcio Debiasi, oncologist at the Breast Unit of the Champalimaud Foundation, presents a study dubbed KeyPARTNER, which is being carried out in this Unit with support from industrial funders. The study’s aim is to optimize the use of chemotherapy together with immunotherapy for the treatment of so-called “triple negative” breast cancers, which are considered to be the most aggressive breast tumours.

Subscribe to Cancer
Loading
Please wait...